| Patient | Jesse Owens |
|---|---|
| Date of birth | 1913-09-12 |
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
| Document date | 1979-10-21 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mr. Owens, now 66, returns for his subsequent annual wellness visit three weeks after his post-operative review; his last wellness visit was at his previous clinic a year ago. He is nine weeks past a thoracoscopic left upper lobectomy, after three cycles of chemoimmunotherapy, and has had no further cancer treatment since. He goes to pulmonary rehabilitation twice a week and walks 2.5 km most mornings. He has not smoked for four and a half months and takes varenicline 1 mg twice daily without side effects. He has gone back to speaking at two schools. He completed the health risk assessment beforehand and asked to talk about what he would want if the cancer came back. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 66 |
| Active conditions | Left upper lobe adenocarcinoma, treated with chemoimmunotherapy and lobectomy (ypT1a N0, R0), now under surveillance; nicotine dependence in early remission on varenicline |
| Medicines | Varenicline 1 mg twice daily; no over-the-counter medicines or supplements |
| Safety events | No falls; no emergency visits since the operation |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with him by Dr. Whitfield-Arroyo. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and getting better |
| Psychosocial | Lives with his wife; daughters call often; church and youth work; worries about the cancer returning, but sleeps well |
| Tobacco | No cigarettes for four and a half months, after 35 years at a pack a day; no vaping |
| Alcohol and drugs | A beer or a glass of wine once or twice a week (AUDIT-C 2); no drugs |
| Physical activity | Walks 2.5 km most mornings and attends pulmonary rehabilitation twice a week |
| Nutrition | Eats regular meals; weight steady since the operation |
| Activities of daily living | Independent in bathing, dressing, eating, toileting and transfers |
| Instrumental activities of daily living | Drives, manages his business, his medicines and his money |
| Home safety | Smoke detectors working; no loose rugs; grab bar in the shower |
| Hearing and vision | Hears well; reading glasses; eye examination two years ago |
| Sun and heat | Walks before the heat of the day and carries water |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; energy returning |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No hoarseness or hearing loss |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Positive | Mild breathlessness on two flights of stairs, improving with rehabilitation; no cough or hemoptysis |
| Gastrointestinal | Negative | No change in bowel habit or black stools |
| Genitourinary | Negative | No urinary symptoms; no blood in the urine |
| Musculoskeletal | Positive | Occasional aching along the left chest wall at the port sites; no bone pain |
| Integumentary | Negative | No rash; incisions healed |
| Neurological | Negative | No numbness, headaches or weakness |
| Psychiatric | Negative | Mood good; PHQ-2 0; no thoughts of self-harm |
| Endocrine | Negative | No heat or cold intolerance |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 1979-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 1979-06-02 to 1979-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 1979-06-03 to 1979-07-31 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery | 1000 mg every 8 hours as needed | Oral route | 1979-08-22 to 1979-09-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-10-21 | Body height | 178 | cm | S |
| 1979-10-21 | Body weight | 75 | kg | S |
| 1979-10-21 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 1979-10-21 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1979-10-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-10-21 | Heart rate | 70 | /min | S |
| 1979-10-21 | Respiratory rate | 16 | /min | S |
| 1979-10-21 | Body temperature | 36.6 | Cel | S |
| 1979-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-10-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1979-10-21 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1979-10-21 | Total score [AUDIT-C] | 2 | {score} | S |
Vital signs recorded on 1979-10-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well and upright; weight 75.0 kg, BMI 23.7; blood pressure 124/76, pulse 70 |
| Eyes | Near vision 20/30 with reading glasses |
| Ears | Whispered-voice test passed on both sides |
| Neck | No lymph nodes; thyroid not enlarged |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Breath sounds slightly reduced at the left apex after the lobectomy; no crackles or wheeze; healed thoracoscopic incisions |
| Musculoskeletal | Timed Up and Go 9 seconds; rises from a chair without using his arms |
| Neurological | Oriented; Mini-Cog 5 of 5; normal gait |
| Skin | No suspicious lesions |
| Psychiatric | Calm, engaged and good-humored |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | resolved | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
| Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor) | active | confirmed | Z90.2 | S — Synthetic consequence of the synthetic operation. |
| Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on varenicline | active | confirmed | F17.211 | S — Synthetic modern entry linked to his documented smoking. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Lung cancer screening | Not indicated | Replaced by surveillance CT after treatment for lung cancer; yearly low-dose CT resumes after the surveillance period |
| Tobacco cessation | Completed today | Abstinent four and a half months; varenicline and quitline support continue |
| Abdominal aortic aneurysm screening | Up to date | One-time screening for men 65 to 75 who have smoked: the infrarenal aorta measured 2.1 cm on the staging CT, normal |
| Colorectal cancer screening | Up to date | Normal colonoscopy four years ago; next in six years |
| Prostate cancer screening | Not indicated | Discussed; at 66, with a cancer under surveillance, he chose not to have a PSA test |
| Hepatitis C screening | Up to date | Negative before chemoimmunotherapy |
| Lipid panel and statin assessment | Ordered | Coronary calcification on CT; fasting lipid panel and A1c ordered |
| Blood pressure screening | Completed today | 124/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 2 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 9 seconds; no falls |
| Influenza vaccine | Completed today | High-dose vaccine given |
| COVID-19 vaccine | Completed today | This season's vaccine given |
| RSV vaccine | Completed today | Single dose for an adult 60 to 74 at increased risk |
| Recombinant zoster vaccine | Completed today | Dose 1 today; dose 2 in two to six months |
| Pneumococcal vaccine | Up to date | PCV20 before chemoimmunotherapy |
| Tetanus, diphtheria, and pertussis | Due | No record of a booster in ten years; Tdap with the second zoster dose |
Immunizations given today: Influenza vaccine, high-dose, this season; COVID-19 mRNA vaccine, this season's formula; Respiratory syncytial virus vaccine, single dose; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(10):962-970 (PMID 33687470) (2021); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Lipid panel and A1c this week. Second zoster dose and Tdap in two to six months. Surveillance CT as booked. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 25 minutes, with his consent. He named a health care agent, recorded in the confidential part of the chart and not named here, and completed an Arizona health care power of attorney. He wants every treatment that offers a real chance of controlling the cancer if it comes back, including more surgery, radiation or medicines. If the cancer returned and could no longer be controlled, he would want his symptoms treated well and to stay at home, with his family and his church, rather than spend his last weeks in intensive care, and he would not want resuscitation in that situation. He wants his story told to young people so that they never start smoking. To be revisited at any change in his health and at least yearly. [S]